Pyxis Oncology, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -73.89M-77.33M
Depreciation and Depletion 0.70M1.80M2.00M
Share-based Compensation 0.04M6.44M15.76M16.95M12.95M
Gains from Investment Securities 1.19M0.60M14.50M0.45M9.71M
Asset Writedowns and Impairment 21.00M
Non-cash Items 12.00M
Cash from Operations -10.08M-35.33M-89.33M-70.71M-57.67M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 4.79M6.11M
Depreciation & Amortization (CF) 0.50M0.65M0.71M1.93M2.98M
Change in Working Capital
Change in Account Payables 0.56M4.64M-8.33M-3.51M1.20M
Change in Accured Expenses 1.74M5.09M11.95M-14.10M-1.67M
Investing Activities
Capital Expenditures 1.48M0.54M6.40M6.73M0.24M
Acquisitions 6.66M
Cash from Investing Activities -1.48M-0.59M-6.40M-104.85M8.15M
Financing Activities
Other financing activities 0.45M
Change in Capital Stock
Shares Issued 0.03M152.30M0.18M0.12M0.30M
Preferred Shares Issued 151.58M
Misc.
Cash from Financing Activities 0.04M304.04M0.18M5.93M59.33M
Change in Cash -11.53M268.13M-95.55M-169.63M9.81M
Free Cash Flow -11.57M-35.87M-95.73M-77.44M-57.91M
Net Cash Flow -11.53M268.13M-95.55M-169.63M9.81M